Free Trial

Shield Therapeutics (LON:STX) Trading Up 11.7% - What's Next?

Shield Therapeutics logo with Medical background

Key Points

  • Shield Therapeutics saw its stock price increase by 11.7%, reaching a trading high of GBX 5.30 before closing at GBX 5.14.
  • The company's market capitalization is currently valued at £50.85 million, with a significant debt-to-equity ratio of 3,691.50.
  • Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency through its product Accrufer®, which has been launched in the U.S.
  • Want stock alerts on Shield Therapeutics? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Shield Therapeutics plc (LON:STX - Get Free Report)'s stock price was up 11.7% during trading on Wednesday . The company traded as high as GBX 5.30 ($0.07) and last traded at GBX 5.14 ($0.07). Approximately 4,623,609 shares traded hands during mid-day trading, an increase of 120% from the average daily volume of 2,102,008 shares. The stock had previously closed at GBX 4.60 ($0.06).

Shield Therapeutics Price Performance

The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The firm has a market capitalization of £50.85 million, a price-to-earnings ratio of -1.33 and a beta of 1.42. The business's fifty day simple moving average is GBX 3.38 and its 200 day simple moving average is GBX 3.04.

Shield Therapeutics Company Profile

(Get Free Report)

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Shield Therapeutics Right Now?

Before you consider Shield Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shield Therapeutics wasn't on the list.

While Shield Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked Stocks Riding the AI Data Center Boom
3 Growth Stock Winners to Watch And 3 to Avoid
3 Growth Stocks That Could Pop Before Summer Ends

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines